Probiotics for the prevention of antibiotic-associated adverse events in children-A scoping review to inform development of a core outcome set.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 18 01 2020
accepted: 08 05 2020
entrez: 30 5 2020
pubmed: 30 5 2020
medline: 25 7 2020
Statut: epublish

Résumé

Routine use of probiotics during antibiotic therapy in children remains a subject of discussion. To facilitate synthesis of individual study results and guideline formulation, it is important to assess predefined, similar, and clinically important outcomes. Core outcome sets are a proposed solution for this issue. The aim of this review was to document choice, design, and heterogeneity of outcomes in studies that assessed the effects of probiotics used for the prevention of antibiotic-associated adverse events in children. A scoping literature search covering three major databases was performed. Studies that evaluated oral probiotics' use concomitant with antibiotic therapy in children were included. Data on outcome definitions, measurement instruments, and follow-up were extracted. The outcomes were assigned to predefined core areas and domains. Data were analyzed descriptively. Thirty-seven studies were included in this review. Diarrhea, the most commonly reported outcome, had diagnostic criteria clearly defined only in 21 studies. In total, 16 different definitions of diarrhea were identified. Diarrhea duration, severity, and etiology were reported in 9, 4, and 7 studies, respectively. Twenty studies assessed gastrointestinal symptoms other than diarrhea. Seven studies reported outcomes related to resource use or the economic impact of the intervention. Only 2 studies assessed outcomes related to life impact. None of the studies predefined adverse events of probiotic use. Identified outcomes were characterized by substantial heterogeneity. The majority of outcomes were not designed to evaluate endpoints of real-life relevance. Results from this review suggest the need for a new core outcome set consisting of outcomes important for decision-making.

Identifiants

pubmed: 32469907
doi: 10.1371/journal.pone.0228824
pii: PONE-D-20-01685
pmc: PMC7259577
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0228824

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Aliment Pharmacol Ther. 2006 Nov 15;24(10):1461-8
pubmed: 17032283
Diabetes Obes Metab. 2018 Jun;20(6):1508-1514
pubmed: 29359849
J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):280-9
pubmed: 23135341
Dig Dis Sci. 1988 Feb;33(2):129-34
pubmed: 3123181
Ann Intern Med. 2018 Aug 21;169(4):240-247
pubmed: 30014150
J Pediatr Gastroenterol Nutr. 2003 Jul;37(1):22-6
pubmed: 12827001
Clin Microbiol Rev. 2015 Jan;28(1):134-64
pubmed: 25567225
Pediatrics. 2012 Dec;130(6):e1447-54
pubmed: 23147969
Pediatr Gastroenterol Hepatol Nutr. 2020 Jan;23(1):35-48
pubmed: 31988874
Pediatr Int. 2003 Feb;45(1):86-90
pubmed: 12654076
J Health Serv Res Policy. 2000 Jan;5(1):27-36
pubmed: 10787584
J Med Assoc Thai. 2002 Aug;85 Suppl 2:S739-42
pubmed: 12403254
BMJ Open. 2015 Jan 14;5(1):e006474
pubmed: 25588782
Pediatr Gastroenterol Hepatol Nutr. 2015 Mar;18(1):17-22
pubmed: 25866729
Benef Microbes. 2013 Dec 1;4(4):329-34
pubmed: 24311316
J Pediatr. 1999 Nov;135(5):564-8
pubmed: 10547243
Front Microbiol. 2017 May 19;8:908
pubmed: 28579981
Lancet. 2003 Feb 8;361(9356):512-9
pubmed: 12583961
J Clin Gastroenterol. 2005 Sep;39(8):692-8
pubmed: 16082279
J Clin Epidemiol. 2014 Jul;67(7):745-53
pubmed: 24582946
Probiotics Antimicrob Proteins. 2018 Jun;10(2):323-328
pubmed: 28871492
JAMA Pediatr. 2017 Feb 1;171(2):150-156
pubmed: 28027334
PLoS One. 2016 Apr 25;11(4):e0154012
pubmed: 27111772
J Med Assoc Thai. 2007 Mar;90(3):513-7
pubmed: 17427529
Ann Intern Med. 2004 Nov 16;141(10):781-8
pubmed: 15545678
Benef Microbes. 2014 Mar;5(1):45-60
pubmed: 24463207
Virus Res. 2014 Sep 22;190:75-96
pubmed: 25016036
Aliment Pharmacol Ther. 2008 Jul;28(1):154-61
pubmed: 18410562
Digestion. 2008;78(1):13-7
pubmed: 18701826
Pediatrics. 1999 Nov;104(5):e64
pubmed: 10545590
World J Microbiol Biotechnol. 2014 Mar;30(3):847-53
pubmed: 24233772
JAMA Pediatr. 2017 Dec 1;171(12):1217-1225
pubmed: 29052687
DICP. 1990 Apr;24(4):382-4
pubmed: 2109432
Clin Microbiol Infect. 2019 Jun;25(6):699-704
pubmed: 30149135
J Pediatr. 2017 Jul;186:82-86
pubmed: 28438377
Lancet Infect Dis. 2015 Oct;15(10):1211-1219
pubmed: 26311042
Ital J Pediatr. 2012 Oct 31;38:63
pubmed: 23114016
Pediatrics. 1985 Sep;76(3):365-70
pubmed: 3875832
Future Microbiol. 2008 Oct;3(5):563-78
pubmed: 18811240
Allergy Asthma Immunol Res. 2018 Sep;10(5):457-465
pubmed: 30088366
Cochrane Database Syst Rev. 2019 Apr 30;4:CD004827
pubmed: 31039287
Arch Pediatr Adolesc Med. 2009 Aug;163(8):750-4
pubmed: 19652108
Scand J Gastroenterol. 1997 Sep;32(9):920-4
pubmed: 9299672
J Pediatr Gastroenterol Nutr. 2016 Jul;63(1):46-50
pubmed: 26859092
J Clin Gastroenterol. 2005 May-Jun;39(5):385-9
pubmed: 15815206
Iran J Pediatr. 2013 Feb;23(1):79-84
pubmed: 23446685
J Pediatr Gastroenterol Nutr. 2016 Mar;62(3):495-506
pubmed: 26756877
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Pediatr Gastroenterol Hepatol Nutr. 2017 Sep;20(3):139-146
pubmed: 29026729
Pediatr Allergy Immunol. 2017 Mar;28(2):170-175
pubmed: 27779809
J Pediatr Gastroenterol Nutr. 2009 Apr;48(4):431-6
pubmed: 19330931
Acta Paediatr. 2009 Jan;98(1):127-31
pubmed: 18681892
Aliment Pharmacol Ther. 2005 Mar 1;21(5):583-90
pubmed: 15740542
J Health Serv Res Policy. 2012 Jan;17(1):1-2
pubmed: 22294719
J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):3-9
pubmed: 28574970
J Public Health (Oxf). 2011 Mar;33(1):147-50
pubmed: 21345890
Pediatrics. 2010 Jul;126(1):e222-31
pubmed: 20566617
J Trop Pediatr. 2004 Aug;50(4):234-6
pubmed: 15357564
Acta Paediatr. 2016 Apr;105(4):e176-80
pubmed: 26821646
JAMA. 2004 May 26;291(20):2457-65
pubmed: 15161896
Saudi Med J. 2015 Mar;36(3):286-90
pubmed: 25737169
Nat Rev Microbiol. 2018 Jul;16(7):410-422
pubmed: 29795328

Auteurs

Jan Łukasik (J)

Department of Pediatrics, Medical University of Warsaw, Warsaw, Poland.

Qin Guo (Q)

Department of Pediatrics, West China Second University Hospital, Chengdu, China.

Leah Boulos (L)

Maritime SPOR SUPPORT Unit, Halifax, Canada.

Hania Szajewska (H)

Department of Pediatrics, Medical University of Warsaw, Warsaw, Poland.

Bradley C Johnston (BC)

Department of Community Health and Epidemiology, Dalhousie University, Halifax, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH